胸腺瘤预后评估研究进展

doi:10.3760/cma.j.issn.1673-422X.2019.12.012

摘要/Abstract

摘要： 胸腺瘤是前纵隔最常见的原发恶性肿瘤，发病率相对较低，关于其预后因素分析的大样本多中心的研究较少，评估胸腺瘤预后的相关指标还处于探索阶段。寻找可能的预测指标进行预后评估，可以掌握诊疗的主动权，把握诊疗时机，为患者提供更好的治疗选择，进而改善患者预后。

关键词: 胸腺瘤, 预后, 胸腺上皮肿瘤

Abstract: Thymoma is the most common primary malignant tumor which occurs in the anterior mediastinum. The incidence of thymoma is relatively low with scarce large sample and multicenter studies available on the prognostic factors of these patients, and the related indexes for evaluating the prognosis are still under investigation. Looking for possible predictive indicators for prognosis evaluation, we can grasp the initiative of diagnosis, seize the opportunity of treatment, and intervene in the poor prognostic factors, thereby improving the prognosis of patients.

Key words: Thymoma, Prognosis, Thymic epithelial tumors

张瑞云, 罗辉, 段永建, 葛红. 胸腺瘤预后评估研究进展[J]. 国际肿瘤学杂志, 2019, 46(12): 764-768.

Zhang Ruiyun, Luo Hui, Duan Yongjian, Ge Hong. Research progress of prognostic evaluation in thymoma[J]. Journal of International Oncology, 2019, 46(12): 764-768.

参考文献［41］

［1］	Komaki R, Gomez DR. Radiotherapy for thymic carcinoma: adjuvant, inductive, and definitive［J］. Front Oncol, 2014, 3: 330. DOI: 10.3389/fonc.2013.00330.
［2］	Modh A, Rimner A, Allen PK, et al. Treatment modalities and outcomes in patients with advanced invasive thymoma or thymic carcinoma: a retrospective multicenter study［J］. Am J Clin Oncol, 2016, 39(2): 120-125. DOI: 10.1097/coc.0000000000000024.
［3］	Meurgey A, Girard N, Merveilleux du Vignaux C, et al. Assessment of the ITMIG statement on the WHO histological classification and of the eighth TNM staging of thymic epithelial tumors of a series of 188 thymic epithelial tumors［J］. J Thorac Oncol, 2017, 12(10): 1571-1581. DOI: 10.1016/j.jtho.2017.06.072.
［4］	Yuan ZY, Gao SG, Mu JW, et al. Long-term outcomes of 307 patients after complete thymoma resection［J］. Chin J Cancer, 2017, 36(1): 46. DOI: 10.1186/s40880-017-0213-8.
［5］	Kocer B, Kaplan T, Gunal N, et al. Longterm survival after R0 resection of thymoma［J］. Asian Cardiovasc Thorac Ann, 2018, 26(6): 461-466. DOI: 10.1177/0218492318778634.
［6］	Tseng YC, Tseng YH, Kao HL, et al. Correction: long term oncological outcome of thymoma and thymic carcinoma-an analysis of 235 cases from a single institution［J］. PLoS One, 2017, 12(9): e0185399. DOI: 10.1371/journal.pone.0185399.
［7］	Liang G, Gu Z, Li Y, et al. Comparison of the Masaoka-Koga staging and the International Association for the Study of Lung Cancer/the International Thymic Malignancies Interest Group proposal for the TNM staging systems based on the Chinese Alliance for Research in Thymomas retrospective database［J］. J Thorac Dis, 2016, 8(4): 727-737. DOI: 10.21037/jtd.2016.03.22.
［8］	Roden AC, Yi ES, Jenkins SM, et al. Reproducibility of 3 histologic classifications and 3 staging systems for thymic epithelial neoplasms and its effect on prognosis［J］. Am J Surg Pathol, 2015, 39(4): 427-441. DOI: 10.1097/pas.0000000000000391.
［9］	Safieddine N, Liu G, Cuningham K, et al. Prognostic factors for cure, recurrence and long-term survival after surgical resection of thymoma［J］. J Thorac Oncol, 2014, 9(7): 1018-1022. DOI: 10.1097/jto.0000000000000215.
［10］	Fukui T, Fukumoto K, Okasaka T, et al. Prognostic impact of tumour size in completely resected thymic epithelial tumours［J］. Eur J Cardiothorac Surg, 2016, 50(6): 1068-1074. DOI: 10.1093/ejcts/ezw178.
［11］	Hwang Y, Park IK, Park S, et al. Lymph node dissection in thymic malignancies: implication of the ITMIG lymph node map, TNM stage classification, and recommendations［J］. J Thorac Oncol, 2016, 11(1): 108-114. DOI: 10.1016/j.jtho.2015.09.001.
［12］	Bian D, Zhou F, Yang W, et al. Thymoma size significantly affects the survival, metastasis and effectiveness of adjuvant therapies: a population based study［J］. Oncotarget, 2018, 9(15): 12273-12283. DOI: 10.18632/oncotarget.24315.
［13］	Nicholson AG, Detterbeck FC, Marino M, et al. The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposals for the T Component for the forthcoming (8th) edition of the TNM classification of malignant tumors［J］. J Thorac Oncol, 2014, 9(9 Suppl 2): S73-S80. DOI: 10.1097/jto.0000000000000303.
［14］	Zhao M, Yin J, Yang X, et al. Nomogram to predict thymoma prognosis: a population-based study of 1312 cases［J］. Thorac Cancer, 2019, 10(5): 1167-1175. DOI: 10.1111/1759-7714.13059.
［15］	杨适泽, 曲晓翰, 赵海斌, 等. 469例胸腺瘤患者预后因素分析［J］. 中华胸心血管外科杂志, 2015, 31(11): 698-699. DOI: 10.3760/cma.j.issn.10014497.2015.11.016.
［16］	袁东风, 谷志涛, 梁光辉, 等. 胸腺瘤合并重症肌无力患者预后的临床研究［J］. 中国肺癌杂志, 2018, 21(1): 1-7. DOI: 10.3779/j.issn.1009-3419.2018.01.01.
［17］	张云峰, 于磊, 景筠, 等. 合并重症肌无力的胸腺瘤治疗与预后特点分析［J］. 中华外科杂志, 2015, 53(8): 612-616. DOI: 10.3760/cma.j.issn.0529-5815.2015.08.012.
［18］	Leuzzi G, Rocco G, Ruffini E, et al. Multimodality therapy for locally advanced thymomas: a propensity score-matched cohort study from the European Society of Thoracic Surgeons Database［J］. J Thorac Cardiovasc Surg, 2016, 151(1): 47-57. e41. DOI: 10.1016/j.jtcvs.2015.08.034.
［19］	Scorsetti M, Leo F, Trama A, et al. Thymoma and thymic carcinomas［J］. Crit Rev Oncol Hematol, 2016, 99: 332-350. DOI: 10.1016/j.critrevonc.2016.01.012.
［20］	章雪飞, 吉春宇, 谷志涛, 等. 血清细胞角蛋白19片段与胸腺肿瘤临床病理特征和预后相关性研究［J］. 中国肺癌杂志, 2018, 21(7): 30-36. DOI: 10.3779/j.issn.1009-3419.2018.07.03.
［21］	Wang W, Liu D, Yang L, et al. CXCR4 overexpression correlates with poor prognosis in myasthenia gravis-associated thymoma［J］. Hum Pathol, 2016, 49: 49-53. DOI: 10.1016/j.humpath.2015.10.007.
［22］	史金胜, 刘美芹, 温静静, 等. 胸腺瘤STAT3表达临床意义分析［J］. 实用肿瘤杂志, 2019, 34(1): 27-30. DOI: 10.13267/j.cnki.syzlzz.2019.01.006.
［23］	Santoni G, Amantini C, Morelli MB, et al. High CTLA-4 expression correlates with poor prognosis in thymoma patients［J］. Oncotarget, 2018, 9(24): 16665-16677. DOI: 10.18632/oncotarget.24645.
［24］	Owen D, Chu B, Lehman AM, et al. Expression patterns, prognostic value, and intratumoral heterogeneity of PD-L1 and PD-1 in thymoma and thymic carcinoma［J］. J Thorac Oncol, 2018, 13(8): 1204-1212. DOI: 10.1016/j.jtho.2018.04.013.
［25］	Yokoyama S, Miyoshi H. Thymic tumors and immune checkpoint inhibitors［J］. J Thorac Dis, 2018, 10(Suppl 13): S1509-S1515. DOI: 10.21037/jtd.2017.10.157.
［26］	Katsuya Y, Fujita Y, Horinouchi H, et al. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma［J］. Lung Cancer, 2015, 88(2): 154-159. DOI: 10.1016/j.lungcan.2015.03.003.
［27］	Yokoyama S, Miyoshi H, Nishi T, et al. Clinicopathologic and prognostic implications of programmed death ligand 1 expression in thymoma［J］. Ann Thorac Surg, 2016, 101(4): 1361-1369. DOI: 10.1016/j.athoracsur.2015.10.044.
［28］	Yokoyama S, Miyoshi H, Nakashima K, et al. Prognostic value of programmed death ligand 1 and programmed death 1 expression in thymic carcinoma［J］. Clin Cancer Res, 2016, 22(18): 4727-4734. DOI: 10.1158/1078-0432.Ccr-16-0434.
［29］	夏钰弘, 杨树东, 郭庆, 等. 胸腺瘤组织c-kit、pten表达变化及其与WHO分型、患者预后的关系［J］. 山东医药, 2018, 58(4): 86-88. DOI: 10.3969/j.issn.1002-266X.2018.04.030.
［30］	张宏毅. 胸腺瘤基因学突变特点［D］. 天津: 天津医科大学, 2017.
［31］	Gong J, Jin S, Pan X, et al. Identification of long noncoding RNAs for predicting prognosis among patients with thymoma［J］. Clin Lab, 2018, 64(7): 1193-1198. DOI: 10.7754/Clin.Lab.2018.180136.
［32］	Wei J, Liu Z, Wu K, et al. Identification of prognostic and subtype-specific potential mirnas in thymoma［J］. Epigenomics, 2017, 9(5): 647-657. DOI: 10.2217/epi-2016-0161.
［33］	Yang G, Zhang W, Yu C, et al. MicroRNA let-7: regulation, single nucleotide polymorphism, and therapy in lung cancer［J］. J Cancer Res Ther, 2015, 11 Suppl 1: C1-C6. DOI: 10.4103/0973-1482.163830.
［34］	Haakensen VD, Nygaard V, Greger L, et al. Subtype-specific micro-RNA expression signatures in breast cancer progression［J］. Int J Cancer, 2016, 139(5): 1117-1128. DOI: 10.1002/ijc.30142.
［35］	Li S, Yuan Y, Xiao H, et al. Discovery and validation of DNA methylation markers for overall survival prognosis in patients with thymic epithelial tumors［J］. Clin Epigenetics, 2019, 11(1): 38. DOI: 10.1186/s13148-019-0619-z.
［36］	Lee GJ, Lee H, Woo IS, et al. Erratum to “high expression level of SOX2 is significantly associated with shorter survival in patients with thymic epithelial tumors” ［Lung Cancer 132 (June) (2019) 9-16］［J］. Lung Cancer, 2019, 136: 160. DOI: 10.1016/j.lungcan.2019.07.012.
［37］	Feng Y, Lei Y, Wu X, et al. GTF2I mutation frequently occurs in more indolent thymic epithelial tumors and predicts better prognosis［J］. Lung Cancer, 2017, 110: 48-52. DOI: 10.1016/j.lungcan.2017.05.020.
［38］	Muriana P, Carretta A, Ciriaco P, et al. Assessment of the prognostic role of neutrophil-to-lymphocyte ratio following complete resection of thymoma［J］. J Cardiothorac Surg, 2018, 13(1): 119. DOI: 10.1186/s13019-018-0805-7.
［39］	Yanagiya M, Nitadori JI, Nagayama K, et al. Prognostic significance of the preoperative neutrophil-to-lymphocyte ratio for complete resection of thymoma［J］. Surg Today, 2018, 48(4): 422-430. DOI: 10.1007/s00595-017-1602-y.
［40］	Szkandera J, Stotz M, Absenger G, et al. Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients［J］. Br J Cancer, 2014, 110(1): 183-188. DOI: 10.1038/bjc.2013.701.
［41］	Janik S, Bekos C, Hacker P, et al. Elevated CRP levels predict poor outcome and tumor recurrence in patients with thymic epithelial tumors: a pro- and retrospective analysis［J］. Oncotarget, 2017, 8(29): 47090-47102. DOI: 10.18632/oncotarget.17478.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[4]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[5]	刘萍萍, 何学芳, 张翼, 杨旭, 张珊珊, 季一飞. 原发性脑胶质瘤患者术后复发危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2024, 51(4): 193-197.
[6]	万芳, 杨钢, 李睿, 万启晶. 食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[7]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[8]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[9]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹. 胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[10]	彭琴, 蔡玉婷, 王伟. KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185.
[11]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[12]	金旭东, 陈忠坚, 毛伟敏. MTAP基因在恶性间皮瘤中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 99-104.
[13]	黄镇, 陈永顺. 循环肿瘤DNA在肝细胞癌诊疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(1): 59-64.
[14]	王潇, 李盈, 罗玉杰, 晋舒. 基于列线图模型探讨血清学指标对鼻咽癌预后的判断价值[J]. 国际肿瘤学杂志, 2023, 50(8): 463-469.
[15]	刘德宝, 孙子雯, 鲁守堂, 徐海东. ASB6在结直肠癌组织中的表达及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 470-474.